




Contents lists available at ScienceDirect

Molecular and Cellular Neuroscience

journal homepage: www.elsevier.com/locate/ymcne

Neuregulin-1 modulates the differentiation of neural stem cells *in vitro* through an interaction with the Swi/Snf complex

D. Pirotte^a, S. Wislet-Gendebien^a, J.M. Cloes^{b,c}, B. Rogister^{a,b,c,d,*}^a Laboratory of Developmental Neurobiology, GIGA-Neurosciences Research Center, University of Liège, Belgium^b Department of Biotechnology, Haute Ecole de la Province de Liège^c Laboratory of Virology and Immunology, GIGA-Infection, Immunity and Inflammation, University of Liège^d Department of Neurology, University of Liège, C.H.U. (B35) Sart Tilman, B-4000 Liège, Belgium

ARTICLE INFO

Article history:

Received 20 April 2009

Revised 24 August 2009

Accepted 8 September 2009

Available online xxxx

Keywords:

Neural stem cells

Differentiation

Neurons

Oligodendrocytes

Neuregulin

Chromatin remodeling complex

ABSTRACT

The neuregulin-1 (*Nrg-1*) gene is translated into several protein isoforms, which are either secreted or membrane-anchored. *In vitro*, neural stem cells (NSC) express mainly the cystein-rich-domain NRG (CRD-NRG) isoform, a membrane-anchored type III form. This isoform exhibits a cystein-rich-domain, which constitutes a second transmembrane domain and can be cleaved to release both a signaling EGF-containing domain (ECD) at the cell surface and an intracellular domain (ICD). The main goal of this paper was to determine the exact role of ECD and ICD in NSC survival and differentiation. Using an siRNA approach, we demonstrated that CRD-NRG inhibition was followed by a decrease in NSC proliferation and of neuronal or oligodendroglial differentiation. Overexpression of ICD but not ECD was followed by a decrease in NSC proliferation and an increase in neuronal and oligodendroglial differentiation. Moreover, we showed that ICD physically interacted in cultured NSC with BRM and BAF57, two members of the Swi/Snf remodeling complex, and that ICD stimulation of neuronal cell differentiation is dependent on the presence of BAF57.

© 2009 Elsevier Inc. All rights reserved.

Introduction

Among growth factors that could modulate nervous system development, neuregulins (NRG) constitute a specialized family of growth factors, which are better known as regulators of various aspects of the nervous system biology (Adlkofer and Lai, 2000; Leimeroth et al., 2002; Lai and Feng, 2004). Each isoform of neuregulin contains an extracellular EGF-like motif, the hallmark of the neuregulin family, which consists of four genes: *Nrg-1* (Britsch, 2007), *Nrg-2* (Carraway et al., 1997; Chang et al., 1997), *Nrg-3* (Hijazi et al., 1998; Zhang et al., 1997) and *Nrg-4* (Harari et al., 1999). The diversity of the *Nrg-1*-encoded protein results from an alternative splicing of a primary transcript (Steinthorsdottir et al., 2004). The *Nrg-1* protein isoforms have been classified into three groups according to the structure of their N-terminal region: type I, or acetylcholine receptor-inducing activity (ARIA) (Corfas et al., 1993), and neu-differentiation factor (NDF) (Wen et al., 1992; Falls et al., 1993); type II, or glial growth factor 2 (GGF2) (Marchionni et al., 1993; Bermingham-McDonogh et al., 1997) and type III, or cystein-rich-domain (CRD-NRG) (Buonanno and Fischbach, 2001). More recently, it was reported that three lesser-known isoforms are also

expressed; type IV, V and VI, leading to 31 isoforms being detected by analysis of human expressed sequence tags (Tan et al., 2007).

All these isoforms are known to exhibit various activities during nervous system development (Esper et al., 2006). Indeed, *Nrg-1*-encoded proteins promote proliferation, differentiation and myelination of Schwann cells (Leimeroth et al., 2002) and oligodendrocytes (Raabe et al., 1996). They also promote maturation and survival of astrocytes (Pinkas-Kramarski et al., 1994). In neurons, *Nrg-1*-encoded neuregulins induce neuronal migration, and selectively increase the expression of several neurotransmitter receptors (Loeb, 2003). They are also implicated in synaptic plasticity (Mei and Xiong, 2008).

The *Nrg-1*-encoded third group protein, CRD-NRG, is expressed by neural stem cells (NSC) in culture (Calaora et al., 2001). CRD-NRG is characterized by two transmembrane regions, and a cleavage releasing the extracellular domain (ECD), which is able to recruit ErbB receptors, and the intracellular domain (ICD) (Frenzel and Falls, 2001). However, ICD has also been detected in neuronal nuclei, suggesting a role in neuronal survival as a consequence of a retrograde signaling mechanism (Bao et al., 2003).

We previously demonstrated that the inhibition of NRG using a recombinant and soluble form of ErbB receptor is followed by a decrease in NSC proliferation and survival and by a premature oligodendroglial differentiation in surviving NSC (Calaora et al., 2001). In this paper, we analyzed the distribution of *Nrg-1*-encoded isoforms in cultured mouse NSC, as well as, in cultured neurons, astrocytes and oligodendrocytes in order to unravel a possible specific distribution of

* Corresponding author. GIGA – Neurosciences Research Center, University of Liège, Avenue de l'Hôpital, 1 – Batiment B36 +1, 4000 Liège – Belgium. Fax: +32 4 366 59 12.
E-mail address: Bernard.Rogister@ulg.ac.be (B. Rogister).

ICD and ECD in immature or differentiated cell types. We then investigated the effects of ECD and ICD on proliferation and differentiation of NSC by modulating their expression. Finally, we demonstrated that ICD can interact with BAF57 (or Smarce1) and Brm (or Smarca2), two members of the Swi/Snf remodeling complex.

Results

Subcellular distribution of the extra- and the intracellular domain in proliferating and differentiating neural stem cells in culture

In order to determine the subcellular distribution of the extracellular domain (ECD) and the intracellular domain (ICD) of *Nrg-1*-encoded isoforms, we performed compartmental protein extractions on proliferating and differentiating cultured neural stem cells (NSC), allowing us to extract specifically either cytoplasmic or membranous or nuclei proteins (see Fig. S3). Bearing in mind the fact that CRD-NRG is the prevalent *Nrg-1*-encoded isoform expressed by proliferating NSC in culture (Calaora et al., 2001) and most available antibodies

recognize either α or β *Nrg-1*-encoded isoforms, we designed a monoclonal antibody against CRD-NRG with an epitope located in the ECD region (a complete description of the D11 monoclonal antibody is available in Fig. S1 and S2).

D11 monoclonal antibody was tested in western blot experiments using compartmental protein extracts. In NSC, a 29 kDa signal was observed in cytoplasmic protein extracts (Fig. 1A), corresponding to the secreted isoform devolved to be released at the cell surface (Loeb et al., 1998). In the membrane protein fraction, we observed a 140 kDa signal corresponding to the full length protein anchored in the membrane (Fig. 1A). An identical profile of the ECD distribution was observed in compartmental extracts prepared using cultured neurons (Fig. 1B). In compartmental protein extracts prepared from cultured astrocytes, the distribution was different, as we observed, in addition to the 29 kDa signal, a 42 kDa signal in the cytoplasmic fraction that could correspond to the NDF isoform (Fig. 1C). Furthermore, the molecular weight of the signal present in the membrane protein fraction was 110 kDa instead of 140 kDa (Fig. 1C), suggesting that D11 monoclonal antibody seemed thus also to recognize type I isoforms. In




Fig. 1. Distribution at the subcellular level of the extracellular and intracellular domain of *Nrg-1*. Western blots using D11 monoclonal antibody allowed us to observe the presence of the full length protein (140 kDa) anchored in the membrane and the secreted form (29 kDa) of the extracellular domain in the cytoplasmic protein extracts from neural stem cells (A) and neurons (B). In astrocytes, we observed a full length form in the membrane protein extracts, which exhibited a 110 kDa molecular weight probably corresponding to the *Nrg-1* type I membrane-anchored isoform. We also identified a 42 kDa signal in cytoplasmic fraction (NDF isoform), which is the secreted form of *Nrg-1* type I (C). In oligodendrocytes, the 140 kDa and 29 kDa were also present as a 120 kDa signal in the cytoplasmic fraction (D). Using an antibody directed against the carboxy-terminal region of *Nrg-1*, we observed a 55 kDa signal in the membrane and nuclear protein extract fractions from the four types of cell (E).




Fig. 2. Efficiency of the inhibition by siRNA transfection of neural stem cells. Three days after siRNA transfection, total proteins of cultured neural stem cells were extracted and analyzed by western blot using anti-Nrg-1, anti-ErbB2 and anti-ErbB4 antibodies. As controls, we used total protein extracts of NSC transfected with a non-target siRNA and with an siRNA against GPHN. The intensity of the specific signal observed in these conditions was quantified by densitometry using the ImageMaster 1D Prime software (GE Healthcare[®]) and was normalized by the signal obtained in each condition using an anti-actin antibody ($N=3$). The results were expressed as a relative percentage of expression compared to non-transfected NSC. The signal specific to each siRNA was reduced in transfected NSC, although the actin signal remained roughly identical.

western blot experiments, D11 antibody, in cultured oligodendrocyte protein extracts, recognized signals at 29 kDa in cytoplasm and at 140 kDa in membrane fractions. We also observed a 120 kDa isoform in cytoplasmic extract and this last form has already been suggested as a proprotein form (Frenzel and Falls, 2001) (Fig. 1D). In each cell type, no signal was observed with D11 monoclonal antibody in the nuclear fractions.

We then performed western blot analyses on the same protein extracts using a commercial polyclonal antibody that recognized an epitope present on the carboxyterminal region of the cytoplasmic extremity. In the four types of cell, we observed a 55 kDa signal in both membrane and nuclear fractions (Fig. 1E). Indeed, these signals could result from a post-translational cleavage of the full length isoform. The Nrg-1 intracellular domain was able to be cleaved by a γ -secretase implicated in a Regulated Intramembrane Proteolysis process (Landman and Kim, 2004). This cleavage then allowed the translocation of the intracellular domain into the nucleus. These results also suggest that it would be possible for ICD to be cleaved and translocated into the nucleus, as was previously demonstrated in Bao et al. (2003).

Knock-down of the expression of Nrg-1-encoded isoforms, and of ErbB2 and ErbB4 in cultured NSC

We first validated our transfection protocol by analyzing the percentage of dissociated NSC transfected with 6-Fam-labeled siRNA and observed that around 50% of cells were transfected (data not shown). Three days after various siRNA transfections, we checked, by western blotting, the efficiency of siRNA against their respective targeted protein expression and we observed a decrease in the signal in NSC cultures for Nrg-1 (Fig. 2A), ErbB2 (Fig. 2B) and ErbB4 (Fig. 2C). A densitometric analysis of the signal obtained by western blot shows that the signal was decreased by at least 45% in comparison with the control, a result which corroborates the efficiency of the transfection.

We then analyzed the effect of siRNA on cultured NSC proliferation by quantifying the Ki67-positive cells (Fig. 3A). The transfection with siRNA directed against Nrg-1-encoded isoforms, and ErbB2 and ErbB4 receptors was followed 3 days later by a statistically significant decrease in the number of Ki67-positive cells. There was no difference observed between the knock-down of ErbB2 or of ErbB4 on the number of Ki67-positive NSC. Concomitantly, the inhibition of Nrg-1 and ErbB2 led to a decrease in the proportion of Ki67-positive NSC, which was different from a statistical point of view. Finally, the decrease observed in response to the knock-down of ErbB4 was statistically more important than the decrease observed with the knock-down of Nrg-1. As the inhibition of the expression of Nrg-1, ErbB2 and ErbB4 appeared roughly equivalent (Fig. 2), these observations would suggest that in addition to Nrg-1-encoded isoforms, the proliferation of NSC in culture could also be sustained by another growth factor interacting with the ErbB4 receptor.

Five days after siRNA transfection, we quantified the numbers of differentiated neurons, oligodendrocytes and astrocytes in the siRNA-transfected NSC cultures. Using immunocytofluorescence, neurons, oligodendrocytes and astrocytes were respectively labeled using anti- β III-tubulin, -O4 and -EAAT1 antibodies and were counted. The number of neurons decreased when NSC were transfected with siRNA directed against Nrg-1-encoded isoforms (Fig. 3B). Interestingly, transfections using siRNA directed against ErbB2 and ErbB4 had no effect on the number of neurons in these identical conditions (Fig. 3B). Similar results were observed when we quantified oligodendrocyte differentiation (Fig. 3C). Finally, the transfection of siRNA directed against the expression of any of these genes was not followed by an effect on the number of astrocytes differentiated from NSC in culture (Fig. 3D). These results indicated that, endogenous Nrg-1-encoded isoforms stimulated the differentiation of neurons and oligodendrocytes in cultured NSC. Moreover, the effect of Nrg-1-encoded isoforms did not require the presence of ErbB2 and ErbB4 receptors, suggesting




Fig. 3. *Nrg-1* plays a role in the proliferation and differentiation of neural stem cells. (A) siRNA-mediated inhibition of *Nrg-1*, *ErbB2* and *ErbB4* expression induced a decrease in the number of proliferating neural stem cells. Three days after siRNA transfection, neural stem cells were fixed with paraformaldehyde and processed for a Ki67 immunolabeling. Twenty fields per coverslip were randomly counted, two coverslips per transfection and a total of eight transfections ($N=8$). In each field, the percentage of Ki67 was calculated with regard to the total cell number (quantified by the number of DAPI-stained nuclei). After siRNA transfection, neural stem cells were also cultivated on adherent surface, in a chemically defined medium without growth factors, to allow them to differentiate. Five days after transfection, cells were fixed and processed for immunolabeling. Twenty fields per coverslip were randomly counted, two coverslips per transfection and a total of eight transfections ($N=8$). (B) An immunolabeling using an anti- β III-tubulin antibody revealed that the number of neurons decreased only after transfection with siRNA *Nrg-1* and not after transfection with siRNA *erbB2* or *erbB4*. (C) An immunolabeling using an anti-O4 antibody revealed that the number of oligodendrocytes decreased only after transfection with siRNA *Nrg-1* but not after transfection with siRNA *erbB2* or *erbB4*. (D) An immunolabeling using an anti-EAAT1 antibody revealed that the number of astrocytes was not modified in any transfection. Results were expressed as a percentage of total cells quantified by DAPI-stained nuclei, except for Graph B where results were expressed as the total number of neurons, given the fact that the quantity of transfected cells per coverslip was adapted to reduce the amount of siRNA and transfecting reagent. Statistical analyses were performed using Student's *t*-test; ** and *** respectively represent $p<0.01$ and $p<0.0005$.

that this effect was not related to an activity of the extracellular domain of these isoforms. As we observed a cleavage of CRD-ICD in NSC cultures, we formulated the hypothesis that this differentiation effect is related only to ICD and its translocation into the nucleus of NSC.

Effects of *Nrg-1* type III extracellular and intracellular domain overexpression in cultured NSC

In order to have a better understanding of the effects of ECD and ICD, we decided to specifically overexpress ECD and ICD in cultured NSC. Three days after transfection with plasmids containing an ECD or ICD sequence, we performed an immunocytofluorescence test using an anti-Ki67 antibody to quantify the NSC proliferation (Fig. 4A). The ECD overexpression did not show any significant change in the number of Ki67-positive NSC compared to the transfected control-NSC. When ICD was overexpressed in NSC, we observed a decrease in the number of Ki67-positive cells, suggesting that ICD could be implicated in the differentiation process. Indeed, 5 days after transfection, analysis by immunocytofluorescence of the number of neurons (β III-tubulin-positive cells), oligodendrocytes (O4-positive

cells) and astrocytes (EAAT1-positive cells) (Figs. 4B–D) showed that overexpression of ICD but not of ECD was followed by an increase in the number of neurons and oligodendrocytes in cultured NSC. No significant changes were observed in the number of astrocytes when ECD or ICD were overexpressed. In order to determine whether the increase in neurons and oligodendrocytes was a consequence of an apoptosis rescue, we performed TUNEL labeling on ICD-transfected NSC and observed no difference between non-transfected and transfected NSC (data not show), indicating thus that ICD does not play a role in the survival of neuron- or oligodendrocyte-differentiating NSC.

Interactions between the intracellular domains of *Nrg-1*, *BAF57* and *Brm*

So far, these results suggested that ICD was responsible for a stimulation of neuronal or oligodendroglial differentiation in NSC cultures. Moreover, these effects were not related to any interaction with *ErbB2* or *ErbB4* receptors. As we also observed that ICD was also present in the nuclear protein extracts of NSC, we formulated the hypothesis that the effects of ICD could be related to a direct interaction with another protein or other proteins. In order to identify




Fig. 4. Proliferation and differentiation of cultured neural stem cells are modulated by the intracellular domain of Nrg-1. The extra- and intracellular domains of the CRD-NRG form of Nrg-1 (respectively CRD-ECD and CRD-ICD) were cloned into pcDNA3.1/V5/His-TOPO. The constructs were then transfected in cultured neural stem cells. (A) The overexpression of Nrg-1 intracellular domain ICD (CRD-ICD) but not ECD (CRD-ECD) reduced the number of proliferating neural stem cells while increasing the number of neurons (B) and oligodendrocytes (C). The proportion of astrocytes did not change after ECD (CRD-ECD) or ICD (CRD-ICD) overexpression (D). After transfection, cells were cultivated and processed for various immunolabelings, as described in Fig. 5. Twenty fields per coverslip were randomly counted, two coverslips per transfection and a total of eight transfections ($N = 8$). Results were expressed as described in Fig. 5. Statistical analyses were performed using Student's *t*-test method; ** and *** respectively represent $p < 0.01$ and $p < 0.0005$.

this (these) protein(s), we decided to use a yeast two-hybrid approach (in collaboration with Hybrigenics^o) and identified an interaction of ICD with BAF57 or Smarce1, a nuclear protein of the Swi/Snf chromatin remodeling complex (Luo and Dean, 1999; Yoo and Crabtree, 2009). These protein complexes are able to modulate DNA/nucleosome interactions, allowing or not transcription through an ATPase activity of a motor protein.

In order to confirm these interactions, we first performed co-immunoprecipitation of cultured NSC protein extract using antibodies directed against BAF57 and Nrg-1 but also against Brg1 and Brm, which are the ATPase subunits of the Swi/Snf chromatin remodeling complex. In those conditions, we observed a signal corresponding to Nrg-1 in immunoprecipitations using BAF57 and Brm antibodies but not Brg1 antibody (Fig. 5A). Similarly, we obtained a signal for BAF57 in immunoprecipitated proteins using Nrg-1, Brg1 and Brm antibodies (Fig. 5B). Western blot analysis using Brm antibody showed a signal after immunoprecipitation with Nrg-1 and BAF57 antibodies (Fig. 5C). Finally, we performed a western blot using Brg1 antibody on immunoprecipitates obtained with Nrg-1 and BAF57, indicating an interaction between Brg1 and BAF57 but not with Nrg-1 (Fig. 5D). In conclusion, this co-immunoprecipitation approach revealed that in NSC, Nrg-1 interacts with BAF57 and Brm but not with Brg1.

In order to validate these immunoprecipitation results, we also used a Tap-tag purification approach, in which ICD was cloned into an expression plasmid in a frame with a dual tag (calmodulin binding

peptide and streptavidin binding peptide) and then expressed in cultured NSC. Three days after transfection in NSC, proteins were extracted and recombinant ICD was purified by a tandem affinity step in mild conditions, allowing a co-purification of NSC proteins that eventually interacted with ICD. We then performed western blots on the purified proteins using antibodies directed against ICD, BAF57 and Brm. In these three western blots, we obtained a signal corresponding to the expected molecular weight (Fig. 5E) confirming that Nrg-1 intracellular domain, BAF57 and Brm were associated in a complex in NSC. A control Tap-tag approach (transfection of NSC with plasmid containing tags but not the ICD sequence) did not show any Nrg-1, BAF57 or Brm signals in those conditions.

The neuronal differentiation of neural stem cells is related to BAF57 recruitment

Taken together, these observations suggested that ICD stimulated the neuronal differentiation of cultured NSC by recruiting the Swi/Snf complex via interactions with Brm and BAF57. To test such a hypothesis, we used a lentivirus expressing an shRNA directed against BAF57 in transduced NSC. Controls were non-infected cultured NSC and cultured NSC infected with a non-target lentivirus. After infection, NSC were then transfected with the ICD expression plasmid. NSC were allowed to differentiate for 5 days *in vitro* and we then counted the number of neurons (β III-tubulin-positive cells) in each condition

(Fig. 6). We were able to observe a decrease in the number of neurons in cultured NSC transduced with a lentivirus expressing shRNA against the expression of BAF57 and this effect was specific, as NSC infected with a non-target lentivirus exhibited the same total number of neurons observed in the non-infected or control condition. Forced ICD expression in cultured NSC was followed by an increase in the number of neurons, as already observed (Fig. 4B). This stimulation of the number of neurons was also observed when cultured NSC were previously infected using a non-target lentivirus. However, the stimulation was completely inhibited when NSC were previously transduced with a lentivirus expressing the shRNA that inhibits BAF57




Fig. 5. The intracellular domain of Nrg-1 interacted with BAF57 and Brm. Total proteins of cultured and untransfected neural stem cells were extracted and an immunoprecipitation with antibodies directed against Nrg-1, BAF57, Brg1 or Brm, followed by western blot using antibodies directed against Nrg-1 (A), BAF57 (B), Brg1 (C) or Brm (D). As a control, we used normal rabbit IgG to immunoprecipitate total proteins of untransfected neural stem cells. These immunoprecipitations demonstrated an endogenous interaction in cultured neural stem cells between BAF57, Nrg-1 and Brm. (E) Proteins extracted from NSC transfected 3 days previously with Tap-tag constructs containing the ICD encoding sequence at either the N-terminal extremity (NTAP) or the C-terminal extremity (CTAP) or not (control CTAP and control NTAP) were purified in a two affinity chromatography step. Eluted proteins were analyzed by western blot using Nrg-1 ICD, BAF57 and Brm antibodies. BAF57 and Brm antibodies showed a signal in CTAP and NTAP conditions but not in the control, indicating that these two proteins co-purified in the two affinity chromatography step with recombinant ICD.




Fig. 6. ICD induced neuronal differentiation of neural stem cells in a BAF57-dependent manner. Dissociated neural stem cells were transduced by lentiviral particles for 1 h. The transfection reagent with ICD-expression plasmid was then added and cells were transferred onto coverslips after 1 h of culture in suspension. Five days after transduction/transfection, cells were paraformaldehyde-fixed and processed for an immunolabeling using anti- β -III-tubulin antibodies. Inhibition of BAF57 expression by shRNA induced a decrease in the number of neurons and this decrease was not compensated by the expression of ICD. Twenty fields per coverslip were randomly counted, two coverslips per transfection and a total of eight transfections ($N=8$). Statistical analyses were performed using Student's *t*-test method; *, ** and *** respectively represent $p < 0.5$, $p < 0.01$ and $p < 0.0005$.

expression, indicating that the positive effect of ICD on the number of neurons in these conditions depends on a BAF57 interaction.

Discussion

Type III Nrg-1 isoform, or CRD-NRG, is known to have two transmembrane domains and to be able to undergo a proteolytic cleavage, releasing both an extracellular domain (ECD) containing the EGF domain known to interact with ErbB receptors and an intracellular domain or ICD (Frenzel and Falls, 2001). It has been demonstrated that ICD can be translocated to the nucleus of various cell types, including neurons, and its involvement has been suggested in a backward signaling mechanism (Bao et al., 2003). Consequently, the main objective of this study was to characterize Nrg-1 activities in NSC using an siRNA approach and a stimulation of expression of ECD and ICD in neural stem cells. In these conditions, we were able to observe that the inhibition of Nrg-1 expression was followed by a decrease in NSC proliferation, which was less pronounced than the siRNA-mediated inhibition of ErbB4 expression. This observation suggested a possible role of one or more other ErbB4 ligands in the stimulation of NSC proliferation and indicates that Nrg-1 mediates a proliferative signal through ErbB4 receptors. However, ErbB4 inhibition has no effect on neuronal and oligodendroglial differentiation. These observations strengthened the hypothesis of ICD backward signaling in oligodendrocyte and neuronal differentiation. Indeed, we found that siRNA-mediated inhibition of Nrg-1 expression in cultured NSC was followed by a decrease in oligodendrocyte numbers, and a stimulation of expression of ICD but not ECD was found to stimulate oligodendrocyte differentiation. All these observations were thus supportive of the idea that stimulation of oligodendroglial differentiation is mediated by Nrg-1, as has been suggested in a previous study (Calaora et al., 2001). However, this previous study used a soluble and truncated form of recombinant erbB3 receptor to inhibit the Nrg-1 signals in NSC cultures and this approach also inhibited all ligands of the EGF family that recognize erbB3. Here, we demonstrated that Nrg-1 and more precisely, ICD or the cytoplasmic

carboxyterminal extremity of the protein is responsible for this stimulation. More interestingly, we observed that neuronal differentiation was regulated by *Nrg-1* and possibly by a similar ICD backward signaling mechanism, as inhibition of *Nrg-1* expression but not of *ErbB4* or *ErbB2* expression was responsible for a decrease in the number of neurons. Moreover, only the stimulation of ICD expression, but not of ECD (part of the *Nrg-1* protein isoforms which does interact with *ErbB* receptors), is responsible for the stimulation of neuronal differentiation.

The hypothesis of the backward signaling of ICD stimulating both neuronal and the oligodendroglial differentiation was supported by the observation that stimulated expression of ICD but not ECD in cultured NSC was followed by an increase in the number of neurons and oligodendrocytes from differentiated NSC. Likewise, the presence of ICD in both membrane and nuclear protein extracts of neurons and of oligodendrocytes was also supportive of a backward signaling of ICD in *in vitro* neuronal and oligodendroglial differentiation. However, the presence of ICD in nuclear extracts of cultured astrocytes would suggest that ICD would act more as a permissive factor than an inducing factor.

In this study, employing a double-hybrid approach using a mouse E10.5–E12.5 brain cDNA library, we unraveled an interaction between *Nrg-1* and BAF57, a member of the Swi/Snf chromatin remodeling complex. Moreover, using both co-immunoprecipitation and Tap-tag, we confirm the interaction between *Nrg-1* and BAF57 and we also demonstrated an interaction between *Nrg-1* and *Brm* but not between *Nrg-1* and *Brg1*. *Brm* and *Brg1* are the ATPases that constitute the two principal subunits of the Swi/Snf chromatin remodeling complex. Although these ATPases are highly homologous, it has been demonstrated that they are associated with different promoters during cellular differentiation (Kadam and Emerson, 2003; Bultman et al., 2000).

BRG1 binds to zinc finger protein through a specific domain that is absent in *Brm*, and *Brm* interacts with ankyrin repeat proteins, which are critical components of Notch signal transduction.

We demonstrated that ICD stimulating activity of neuronal differentiation was mediated through a recruitment of BAF57, as the inhibition of its expression prevented the ICD effect. This last result implicated the Swi/Snf complex in neuronal differentiation, and it has recently been demonstrated that a switch of the components from this complex is related to the transition of NSC to neurons (Lessard et al., 2007). In this context, it is possible that ICD participates in such a switch.

In conclusion, we demonstrated that *in vitro*, the intracellular domain ICD of type III *Nrg-1* isoform or CRD-NRG expressed by NSC was implicated in a backward signaling mechanism, allowing a stimulation of neuronal and oligodendroglial differentiation. This effect, appearing as a permissive effect, was related to an interaction with BAF57 and possibly with *Brm*, both of the Swi/Snf remodeling complex.

Experimental methods

Preparation of NSC culture

NMRI mice embryos (Harlan^o, Kreuzelweg, The Netherlands) were used as the source of neural stem cells and were euthanized by cervical dislocation. E16 mice striata were removed and mechanically dissociated in DEM/F12 (Invitrogen^o, Brussels, Belgium) (1:1, v/v). The cell suspension was filtered through a 70 μ m-pore filter, then plated on uncoated T75 tissue culture flasks (NUNC^o, Langensfeld, Germany) at 1×10^6 cells/20 ml in DEM/F12 supplemented with B27 (Invitrogen^o) and 20 ng/ml of EGF (Sigma^o, Bornem, Belgium). The medium was supplemented with EGF every 3 days. Proliferating spheres were collected after 5 to 7 days in culture as floating neurospheres.

Astrocyte culture

Astrocytes were obtained from neonatal NMRI mouse cortices that were freed of meninges, minced into small pieces of tissue with microscissors and then suspended in MEM (Invitrogen^o) supplemented with glucose 6 g/l and 10% FCS (Invitrogen^o) and successively filtered through a 225 μ m-pore and a 25 μ m-pore filter. The filtered cell suspension was plated on an uncoated T25 flask for 72 h. The medium was then changed and cells were grown until confluence.

Neuron culture

E16 mice hippocampi were removed and suspended into 0.25% trypsin and 0.01% DNase (Sigma^o) at 3 $^{\circ}$ C for 20 min. The enzymatic reaction was stopped by adding 10% FCS. The hippocampi were then washed with fresh medium and dissociated in DMEM medium (Invitrogen^o) supplemented with glucose 6 g/l, insulin 5 μ g/ml (Sigma^o), 10% horse serum (Invitrogen^o) and 5% FCS. The cell suspension was plated onto Petri dishes previously coated with 0.1 mg/ml polyornithine and cultured in the same medium. Contaminating astrocyte proliferation was inhibited by two successive cytosine arabinoside Ara-C 10^{-5} M (Sigma^o) treatments in DMEM medium supplemented with 5% horse serum and 10% FCS for 24 h.

Oligodendrocyte culture

E16 mice cortices were mechanically dissociated and the cell suspension was layered on top of a pre-centrifuged (30 min at 26,000 \times g). Percoll density gradient (GE Healthcare^o, Roosendaal, The Netherlands 1.04 g/ml) was centrifuged for 15 min at 26,000 \times g. Cell debris that remained in the top aqueous phase was discarded and the interphase below the debris and just above the red blood cells was resuspended in PBS–HEPES. The suspension was centrifuged three times (10 min at 400 \times g) in PBS–HEPES to eliminate Percoll. The final pellet was resuspended in DMEM supplemented with 10 ng/ml PDGF-AA (Preprotech^o, Rocky Hill, New Jersey, USA) and 10 ng/ml biotin (Sigma^o). After 3 days, oligospheres were formed and then plated on T25 plates previously coated with 0.1 mg/ml polyornithine in DMEM supplemented with 0.5% FCS. Oligodendrocytes were collected after 3 days of differentiation.

Compartmental protein extraction

Proteins were extracted from mouse E16 striata, floating spheres and cultured neurons, astrocytes and oligodendrocytes. Neurospheres were collected by centrifugation 10 min at 1000 \times g and differentiated cells were collected by scrapping. Cells were harvested in hypotonic buffer–Tris 20 mM, phosphatase inhibitors 1:20 (ActiveMotif^o, Rixensart Belgium), and Complete protease inhibitor cocktail (Roche^o, Brussels, Belgium). Extractions were fractionated into soluble proteins (fraction I) and non-soluble proteins (fraction II) by centrifugation at 400 \times g for 10 min at 4 $^{\circ}$ C. Fraction II (which contained nuclear proteins) was resuspended in lysis buffer (Active Motif^o) and incubated for 30 min at 4 $^{\circ}$ C under gentle agitation, then centrifuged at 14,000 \times g for 10 min. This step allowed the recovery of nuclear proteins in the supernatant (fraction III). Fraction I was then centrifuged at 125,000 \times g for 30 min at 4 $^{\circ}$ C. The supernatant (fraction IV) contained soluble cytoplasmic proteins and the pellet (fraction V) contained membrane proteins. Fraction V was resuspended in MBS buffer (MES 25 mM, NaCl 50 mM, 1% Triton X-100). Protein concentrations were quantified by the RC/DC Protein Assay (Bio-Rad^o, Nazareth, Belgium) based on the classical method of Lowry.

Western blots

Equivalent amounts of extracted proteins were loaded on each lane of a 10% polyacrylamide gel (Nupage, Invitrogen®). After electrophoresis, proteins were transferred onto PVDF membrane (Roche®). After blocking in 0.2% purified casein (Tropix®, Bedford, MA, USA), the membrane was incubated with primary antibody overnight at 4 °C and then with a secondary antibody conjugated with peroxidase for 1 h at room temperature. Immunoreactive signals were visualized by enhanced chemiluminescence (Super-Signal WestPico, Pierce®, Brussels, Belgium). Primary antibodies used were: D11 monoclonal antibody (home made, see [Supplementary data](#)); Nrg-1/ICD (Upstate®, Dundee, UK; 1:1000); actin (AbCam®, Cambridge, UK; 1:200); ErbB2 (Santa Cruz®, California, USA; 1/200); ErbB4 (Santa Cruz®; 1/200); BAF57 (Sigma®; 1:1000); Brg1 (Abcam®; 1/1000) and Brm (Abcam®; 1/750). Secondary antibodies conjugated with peroxidase were RG-16 mouse monoclonal anti-rabbit (AbCam®) used at 1:3000, and goat anti-mouse (Sigma®) used at 1:2000.

Transfection with plasmid constructs

The extra- and intracellular domains of CRD-NRG (respectively ECD and ICD) were amplified by PCR (primer sequences displayed in [Table 1](#)) – using as a template the previously CRD-NRG cloned cDNA (Bermingham-McDonogh et al., 1997) – and were inserted into pcDNA3.1/V5/His-TOPO (Invitrogen®). Plasmid constructions were sequenced. For the purpose of transfection, neurospheres were mechanically dissociated and individualized NSC were then transfected in suspension using Fugene® HD (Roche®) according to the manufacturer's instructions. Cells were then plated on laminin-coated coverslips (0.01 mg/ml) for 48–96 h.

Transfection with siRNA

Before transfection, neurospheres were mechanically dissociated and filtered through a 10 µm-pore filter. The filtered cell suspension was transfected with 200 nM of siRNA (sequences displayed in [Table 2](#)) (Ambion®, Lennik, Belgium). Transfections were performed using Neofectine® (Ambion®) according to the manufacturer's instructions. Transfected cells were then plated on laminin-coated (0.01 mg/ml) coverslips for 72–120 h.

Immunocytofluorescence

Cells were fixed with 4% paraformaldehyde for 20 min at room temperature, and were then permeabilized and blocked (unspecific binding sites) by a 30 min incubation at room temperature in blocking solution (10% donkey serum and 0.3% Triton X-100 in 1×PBS). Cells were then incubated for 1 h at RT with primary antibodies diluted in a 10% donkey serum and 0.1% Triton X-100 in PBS. We used antibodies directed against Ki67 (BD Biosciences®, Erembodegem, Belgium; 1:250), EAAT1 (AbCam®; 1:250), βIII-tubulin (Millipore®, Brussels, Belgium; 1:1000), and O4 (Millipore®, 1:100). Cells were washed and incubated with secondary antibodies: FITC conjugated donkey anti-mouse (Jackson ImmunoResearch®, West Grove, USA; 1:500) or rhodamine conjugated donkey anti-rabbit (Jackson ImmunoResearch®, 1:500). Immunostained cover-

Table 2

Sequences of the sense and antisense oligonucleotides used as siRNA after annealing.

	Sense	Antisense
siRNA <i>Nrg-1</i>	CCAAGUAAUGUCCAAUAAU	AUUAAUUGGACAUUACUUGG
siRNA <i>ErbB2</i>	GGGAGGAGUUUUGAUCCGU	ACGGAUCAAACUCCUCC
siRNA <i>ErbB4</i>	CCUGACCGAAUACUAAAU	AUUUAGUAAUUCGGUCAGG
siRNA <i>GPHN</i>	GCCCUUAGUCUUUAGACG	CGUCUUAAGACUAAGGGC

slips were imaged and examined using a laser-scanning confocal microscope equipped with a krypton/argon gas layer (Olympus® Fluoview 1000, Aartselaar, Belgium). Positive cells were counted within 20 randomly selected microscope fields per coverslip.

Immunoprecipitation

Cells were harvested in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 3 mM EDTA and 1% Triton X-100), supplemented with phosphatase inhibitors (Roche®) and protease inhibitors (Complete, Roche®). Lysates were clarified by centrifugation at 16,000×g for 20 min at 4 °C. Supernatants were precleared with Protein G-agarose (Roche®) for 1 h and then incubated with 2 µg of normal rabbit IgG as a negative control (Santa Cruz®), Nrg-1/ICD (Upstate®), BAF57 (Sigma®), Brg1 (Abcam®) or Brm (Abcam) for 2 h at 4 °C. Protein G-agarose was then added for an overnight incubation at 4 °C. After centrifugation, immunoprecipitates were washed 3 times in lysis buffer and were subjected to western blot analysis after elution in electrophoresis loading buffer.

Tap-tag purification

The intracellular domain (ICD) of Nrg-1 was amplified by PCR (sequences displayed in [Table 3](#)) using as a template the previously CRD-NRG cloned cDNA, and it was then cloned into pCTAP and pNTAP expression vectors (Stratagene®, La Jolla, United States). Both vectors contained two Tap-tags, a streptavidin binding peptide (SBP) and a calmodulin binding peptide (CBP), resulting in the fusion of the Tap-tags to the C-terminus (pCTAP) or N-terminus (pNTAP) of the intracellular domain. Plasmids were prepared using Sigma MidiPrep Kits (Sigma®), checked by sequencing. Dissociated NSC were transfected with these plasmids by electroporation (BTX® ECM 830 apparatus, 1 pull, 100 V, 10 ms). Transfected cells were plated on uncoated T75 tissue culture flasks at 2×10⁶ cells/20 ml (NUNC®, Langenselbold, Germany) in DEM/F12 (Invitrogen®) supplemented with B27 (Invitrogen®) for 3 days. Cells were then collected and resuspended in lysis buffer provided with the InterPlay TAP Purification Kit (Stratagene®).

Lentiviral transduction

Dissociated and filtered neurospheres were transduced by addition of 100 µl lentivirus expressing shRNA directed against BAF57 (Sigma®) for 1 h at 37 °C. The cell suspension was mixed every 15 min to avoid the formation of aggregates. A proportion of the cells was also transfected with plasmid containing the ICD sequence, as explained previously. Transduced cells were plated onto laminin-coated (0.01 mg/ml) coverslips. We used non-target lentivirus (Sigma®) as a negative control and lentivirus turboGFP as a positive control (Sigma®).

Table 1

Sequences of primers used for amplification of CRD-ECD and CRD-ICD sequences.

CRD-ECD for	5' CACCATGGAGATTATTTCCCCAG 3'
CRD-ECD rev	5' GATGCCAGTAATTGTGACGCAAC 3'
CRD-ICD for	5' CACCAATTACTGGCATCTGTATC3'
CRD-ICD rev	5' TACAGCAATAGGGTCTTGTTAG 3'

Table 3

Sequences of the primers used for PCR amplification of CRD-ICD before cloning into pNTAP or pCTAP.

Tap-tag NRG-ICD for	5' AGCGATATCTGCTGACAATTACTGGCATCTG 3'
Tap-tag NRG-ICD rev	5' AGCCTCGAGTACAGCAATAGGGTCTTGTTAG 3'

Acknowledgments

This study was supported by a grant from the Fonds National de la Recherche Scientifique (FNRS) of Belgium, by a grant from the Action de Recherche Concertée de la Communauté Française de Belgique, and by the Belgian League against Multiple Sclerosis. S.W. is a postdoctoral researcher of the FNRS and D.P. is research fellow of the FRiA.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.mcn.2009.09.003.

References

- Adlkofer, K., Lai, C., 2000. Role of neuregulins in glial cell development. *Glia* 29, 104–111.
- Bao, J., Wolpowitz, D., Role, L.W., Talmage, D.A., 2003. Back signaling by the Nrg-1 intracellular domain. *J. Cell Biol.* 161, 1133–1141.
- Bermingham-McDonogh, O., Xu, Y.T., Marchionni, M.A., Scherer, S.S., 1997. Neuregulin expression in PNS neurons: isoforms and regulation by target interactions. *Mol. Cell. Neurosci.* 10, 184–195.
- Britsch, S., 2007. The neuregulin-1/ErbB signaling system in development and disease. *Adv. Anat. Embryol. Cell Biol.* 190, 1–65.
- Bultman, S., Gebuhr, T., Yee, D., La Mantia, C., Nicholson, J., Gilliam, A., Randazzo, F., Metzger, D., Chambon, P., Crabtree, G., Magnuson, T., 2000. *Mol. Cell* 1287–1295.
- Buonanno, A., Fischbach, G.D., 2001. Neuregulin and ErbB receptor signaling pathways in the nervous system. *Curr. Opin. Neurobiol.* 11, 287–296.
- Calaora, V., Rogister, B., Bismuth, K., Murray, K., Brandt, H., Leprince, P., Marchionni, M., Dubois-Dalcq, M., 2001. Neuregulin signaling regulates neural precursor growth and the generation of oligodendrocytes in vitro. *J. Neurosci.* 21, 4740–4751.
- Carraway III, K.L., Weber, J.L., Unger, M.J., Ledesma, J., Yu, N., Gassmann, M., Lai, C., 1997. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. *Nature* 387, 512–516.
- Chang, H., Riese, D.J., Gilbert, W., Stern, D.F., McMahan, U.J., 1997. Ligands for ErbB-family receptors encoded by a neuregulin-like gene. *Nature* 387, 509–512.
- Corfas, G., Falls, D.L., Fischbach, G.D., 1993. ARIA, a protein that stimulates acetylcholine receptor synthesis, also induces tyrosine phosphorylation of a 185-kDa muscle transmembrane protein. *Proc. Natl. Acad. Sci. U. S. A.* 90, 1624–1628.
- Esper, R.M., Pankonin, M.S., Loeb, J.A., 2006. Neuregulins: versatile growth and differentiation factors in nervous system development and human disease. *Brain Res. Rev.* 51, 161–175.
- Falls, D.L., Rosen, K.M., Corfas, G., Lane, W.S., Fischbach, G.D., 1993. ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. *Cell* 72, 801–815.
- Frenzel, K.E., Falls, D.L., 2001. Neuregulin-1 proteins in rat brain and transfected cells are localized to lipid rafts. *J. Neurochem.* 77, 1–12.
- Harari, D., Tzahar, E., Romano, J., Shelly, M., Pierce, J.H., Andrews, G.C., Yarden, Y., 1999. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. *Oncogene* 18, 2681–2689.
- Hijazi, M.M., Young, P.E., Dougherty, M.K., Bressette, D.S., Cao, T.T., Pierce, J.H., Wong, L.M., Alimandi, M., King, C.R., 1998. NRG-3 in human breast cancers: activation of multiple erbB family proteins. *Int. J. Oncol.* 13, 1061–1067.
- Kadam, S., Emerson, B.M., 2003. Transcriptional specificity of human SWI/SNF BRG1 and BRM chromatin remodeling complexes. *Mol. Cell* 11 (2), 377–389.
- Lai, C., Feng, L., 2004. Neuregulin induces proliferation of neural progenitor cells via PLC/PKC pathway. *Biochem. Biophys. Res. Commun.* 319, 603–611.
- Landman, N., Kim, T.W., 2004. Got RIP? Presenilin-dependent intramembrane proteolysis in growth factor receptor signaling. *Cytokine Growth Factor Rev.* 15, 337–351.
- Leimerth, R., Lobsiger, C., Lussi, A., Taylor, V., Suter, U., Sommer, L., 2002. Membrane-bound neuregulin1 type III actively promotes Schwann cell differentiation of multipotent progenitor cells. *Dev. Biol.* 246, 245–258.
- Lessard, J., Wu, J.L., Ranish, J.A., Wan, M., Winslow, M.M., Staahl, B.T., Wu, H., Aebersold, R., Graef, I.A., Crabtree, G.R., 2007. An essential switch in subunit composition of a chromatin remodeling complex during neural development. *Neuron* 19 (55(2)), 201–215.
- Loeb, J.A., 2003. Neuregulin: an activity-dependent synaptic modulator at the neuromuscular junction. *J. Neurocytol.* 32, 649–664.
- Loeb, J.A., Susanto, E.T., Fischbach, G.D., 1998. The neuregulin precursor proARIA is processed to ARIA after expression on the cell surface by a protein kinase C-enhanced mechanism. *Mol. Cell. Neurosci.* 11, 77–91.
- Luo, R.X., Dean, D.C., 1999. Chromatin remodeling and transcriptional regulation. *J. Natl. Cancer Inst.* 91, 1288–1294.
- Marchionni, M.A., Goodearl, A.D., Chen, M.S., Bermingham-McDonogh, O., Kirk, C., Hendricks, M., Danehy, F., Misumi, D., Sudhalter, J., Kobayashi, K., et al., 1993. Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. *Nature* 362, 312–318.
- Mei, L., Xiong, W.C., 2008. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. *Nat. Rev. Neurosci.* 9, 437–452.
- Pinkas-Kramarski, R., Eilam, R., Spiegler, O., Lavi, S., Liu, N., Chang, D., Wen, D., Schwartz, M., Yarden, Y., 1994. Brain neurons and glial cells express Neu differentiation factor/hergulin: a survival factor for astrocytes. *Proc. Natl. Acad. Sci. U. S. A.* 91, 9387–9391.
- Raabe, T.D., Clive, D.R., Neuberger, T.J., Wen, D., Devries, G.H., 1996. Cultured neonatal Schwann cells contain and secrete neuregulins. *J. Neurosci. Res.* 46, 263–270.
- Steinthorsdottir, V., Stefansson, H., Ghosh, S., Birgisdottir, B., Bjornsdottir, S., Fasquel, A.C., Olafsson, O., Stefansson, K., Gulcher, J.R., 2004. Multiple novel transcription initiation sites for NRG1. *Gene* 342, 97–105.
- Tan, W., Wang, Y., Gold, B., Chen, J., Dean, M., Harrison, P.J., Weinberger, D.R., Law, A.J., 2007. Molecular cloning of a brain-specific, developmentally regulated neuregulin 1 (NRG1) isoform and identification of a functional promoter variant associated with schizophrenia. *J. Biol. Chem.* 282, 24343–24351.
- Wen, D., Peles, E., Cupples, R., Suggs, S.V., Bacus, S.S., Luo, Y., Trail, G., Hu, S., Silbiger, S.M., Levy, R.B., et al., 1992. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. *Cell* 69, 559–572.
- Yoo, A., Crabtree, G., 2009. ATP-dependent chromatin remodeling in neural development. *Curr. Opin. Neurobiol.* 19, 120–126.
- Zhang, D., Sliwkowski, M.X., Mark, M., Frantz, G., Akita, R., Sun, Y., Hillan, K., Crowley, C., Brush, J., Godowski, P.J., 1997. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. *Proc. Natl. Acad. Sci. U. S. A.* 94, 9562–9567.